Related Experiment Video
Updated: Aug 30, 2026
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification
1Fresenius Medical Care of Bethlehem, Bethlehem, PA 18017, USA. clp1rd@aol.com
Insights
This case study shows how optimizing phosphorus management with calcium-free binders improved mineral control in a hemodialysis patient, reducing cardiovascular calcification risk. The patient experienced no further myocardial infarctions after treatment adjustments.
Area of Science:
- Nephrology
- Cardiology
- Mineral Metabolism
Background:
- Dialysis patients often face challenges with mineral and bone disorders, particularly managing phosphorus levels.
- Elevated calcium-phosphate product is a known risk factor for cardiovascular calcification and adverse events.
Observation:
- A maintenance hemodialysis patient developed atherosclerotic coronary calcification and myocardial infarction.
- High calcium intake over six years potentially contributed to coronary artery disease before risks were fully understood.
Findings:
- The patient's serum calcium peaked at 10.8 mg/dL before the cardiac event, with a Ca x P product of 57 mg2/dL2.
- Optimizing phosphorus binders, including calcium-free sevelamer hydrochloride, stabilized serum calcium at 8.5 mg/dL and reduced the Ca x P product to 50.7 mg2/dL2.
- The patient experienced no further myocardial infarctions after treatment optimization.
Implications:
- Improved understanding of phosphorus management and the use of calcium-free binders enhance mineral balance in dialysis patients.
- This approach can effectively reduce the risk of cardiovascular calcification and associated complications.
- Personalized therapeutic strategies are crucial for managing complex mineral disorders in chronic kidney disease.
Objective:
To report parameters and outcomes of phosphorus management in a maintenance hemodialysis patient who experienced atherosclerotic coronary calcification leading to myocardial infarction; to evaluate the role that high calcium intake over 6 years may have played in his coronary artery disease before the dangers of excess calcium intake in phosphorus management were recognized; and to describe an optimized therapeutic approach that provided improved mineral control.
Design:
Case study.
Setting:
A large outpatient in-center hemodialysis treatment unit.
Main Outcome Measures:
Serum calcium, serum phosphorus, Ca x P product.
Results:
The year before his cardiac event, the patient's mean serum calcium was 9.6 mg/dL, mean serum phosphorus was 5.9 mg/dL, and mean Ca x P product was 57 mg2/dL2. Serum calcium peaked at 10.8 mg/dL shortly before his cardiac event. Treatment phases included high-dose calcium acetate (10 g Ca/day), low-dose calcium acetate (4 g Ca/day), low-dose calcium acetate plus low-dose sevelamer hydrochloride (4 g Ca/day plus 2.4 to 4.8 g sevelamer/day), and low-dose calcium acetate plus higher-dose sevelamer hydrochloride (4 g Ca/day plus 4.0 to 12.0 g sevelamer/day). With calcium acetate and sevelamer doses optimized, serum phosphorus levels and Ca x P products continued decreasing, with mean values of 5.99 mg/dL and 50.7 mg2/dL2, respectively, and serum calcium remained stable at a mean of 8.5 mg/dL. The patient has had no further myocardial infarctions.
Conclusions:
This case illustrates how our growing understanding of phosphorus management and the addition of a calcium-free binder to our therapeutic armamentarium have improved phosphorus and calcium balance, reducing the risk of cardiovascular calcification.
Related Concept Videos
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:21Skeleton and Calcium Homeostasis